Microbial metabolites: cause or consequence in gastrointestinal disease?

Area of Science:

• Microbiome research
• Systems biology
• Natural product chemistry

Background:

• Gastrointestinal microbiome dysbiosis is associated with various diseases, including inflammatory bowel diseases, cancer, and infections.
• Mechanistic data linking specific microbial taxa to host pathophysiology is scarce.
• Microbes produce signaling molecules, including specialized metabolites, that influence host-microbiome interactions.

Purpose of the Study:

• To explore the role of bioactive natural products encoded by the human microbiome in gastrointestinal diseases.
• To investigate the contribution of microbial metabolites to cancer, autoimmune disorders, and infections.
• To present strategies for discovering these microbial compounds and their therapeutic potential.

Main Methods:

• Review of systems biology studies on host-microbiome interactions.
• Analysis of microbial biosynthetic gene clusters (RiPPs, NRPs, PKs, terpenes).
• Examination of microbial metabolite signaling pathways.

Main Results:

• Microbial metabolites, particularly those from biosynthetic gene clusters, play a significant role in host physiology and disease.
• Specific microbial taxa and their effector pathways are linked to disease states.
• Discovery of novel bioactive natural products from the microbiome offers therapeutic opportunities.

Conclusions:

• Understanding the molecular causation of gut microbiome research is crucial for developing novel diagnostic and therapeutic strategies.
• Bioactive natural products from the microbiome represent a promising area for drug discovery.
• Further research into microbial metabolites can lead to better prevention and treatment of gut-related diseases and infections.